Which has stronger earnings and valuation, AKTS or ERAS?

Aktis Oncology has higher revenue and earnings than Erasca. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aktis Oncology $6.50M 180.16 N/A N/A N/A Erasca N/A N/A -$124.55M -$0.93 N/A

Is AKTS or ERAS more profitable?

Aktis Oncology's return on equity of 0.00% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Erasca N/A -35.31% -29.49%

Does the media prefer AKTS or ERAS?

In the previous week, Erasca had 20 more articles in the media than Aktis Oncology. MarketBeat recorded 24 mentions for Erasca and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.47 beat Erasca's score of -0.20 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 1 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 6 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, AKTS or ORKA?

Aktis Oncology has higher revenue and earnings than Oruka Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aktis Oncology $6.50M 180.16 N/A N/A N/A Oruka Therapeutics N/A N/A -$105.43M -$1.94 N/A

Is AKTS or ORKA more profitable?

Aktis Oncology's return on equity of 0.00% beat Oruka Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Oruka Therapeutics N/A -26.16% -25.00%

Does the media favor AKTS or ORKA?

In the previous week, Oruka Therapeutics had 1 more articles in the media than Aktis Oncology. MarketBeat recorded 5 mentions for Oruka Therapeutics and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.47 beat Oruka Therapeutics' score of 0.19 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, CPRX or AKTS?

Catalyst Pharmaceuticals has higher revenue and earnings than Aktis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Catalyst Pharmaceuticals $588.99M 6.52 $214.33M $1.74 18.02 Aktis Oncology $6.50M 180.16 N/A N/A N/A

Which has preferable valuation and earnings, AKTS or MANE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aktis Oncology $6.50M 180.16 N/A N/A N/A Veradermics N/A N/A N/A N/A N/A

Is AKTS or MANE more profitable?

Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Veradermics N/A N/A N/A

Does the media favor AKTS or MANE?

In the previous week, Aktis Oncology had 2 more articles in the media than Veradermics. MarketBeat recorded 4 mentions for Aktis Oncology and 2 mentions for Veradermics. Veradermics' average media sentiment score of 0.54 beat Aktis Oncology's score of 0.47 indicating that Veradermics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Veradermics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, AKTS or KNSA?

Kiniksa Pharmaceuticals International has higher revenue and earnings than Aktis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aktis Oncology $6.50M 180.16 N/A N/A N/A Kiniksa Pharmaceuticals International $677.56M 5.89 $59.01M $0.90 57.66

Aktis Oncology (AKTS) Competitors

$21.93 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$22.52 +0.59 (+2.71%)

As of 06/12/2026 07:59 PM Eastern

Compare

AKTS vs. ERAS, ORKA, CPRX, MANE, and KNSA

Should you buy Aktis Oncology stock or one of its competitors? MarketBeat compares Aktis Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aktis Oncology include Erasca (ERAS), Oruka Therapeutics (ORKA), Catalyst Pharmaceuticals (CPRX), Veradermics (MANE), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

How does Aktis Oncology compare to Erasca?

Aktis Oncology (NASDAQ:AKTS) and Erasca (NASDAQ:ERAS) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aktis Oncology has higher revenue and earnings than Erasca.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	180.16	N/A	N/A	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Aktis Oncology currently has a consensus target price of $32.50, indicating a potential upside of 48.20%. Erasca has a consensus target price of $20.11, indicating a potential upside of 43.14%. Given Aktis Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe Aktis Oncology is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Aktis Oncology's return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Erasca	N/A	-35.31%	-29.49%

In the previous week, Erasca had 20 more articles in the media than Aktis Oncology. MarketBeat recorded 24 mentions for Erasca and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.47 beat Erasca's score of -0.20 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	1 Very Positive mention(s)	1 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	6 Very Negative mention(s)	Neutral

Summary

Aktis Oncology beats Erasca on 6 of the 10 factors compared between the two stocks.

How does Aktis Oncology compare to Oruka Therapeutics?

Aktis Oncology (NASDAQ:AKTS) and Oruka Therapeutics (NASDAQ:ORKA) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Aktis Oncology's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Oruka Therapeutics	N/A	-26.16%	-25.00%

In the previous week, Oruka Therapeutics had 1 more articles in the media than Aktis Oncology. MarketBeat recorded 5 mentions for Oruka Therapeutics and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.47 beat Oruka Therapeutics' score of 0.19 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aktis Oncology presently has a consensus price target of $32.50, indicating a potential upside of 48.20%. Oruka Therapeutics has a consensus price target of $131.30, indicating a potential upside of 87.87%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aktis Oncology has higher revenue and earnings than Oruka Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	180.16	N/A	N/A	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Summary

Oruka Therapeutics beats Aktis Oncology on 6 of the 10 factors compared between the two stocks.

How does Aktis Oncology compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Aktis Oncology (NASDAQ:AKTS) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

In the previous week, Aktis Oncology had 3 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 4 mentions for Aktis Oncology and 1 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.43 beat Aktis Oncology's score of 0.47 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Positive
Aktis Oncology	Neutral

Catalyst Pharmaceuticals has higher revenue and earnings than Aktis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.52	$214.33M	$1.74	18.02
Aktis Oncology	$6.50M	180.16	N/A	N/A	N/A

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Catalyst Pharmaceuticals presently has a consensus target price of $32.00, indicating a potential upside of 2.04%. Aktis Oncology has a consensus target price of $32.50, indicating a potential upside of 48.20%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Aktis Oncology is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Aktis Oncology's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Aktis Oncology	N/A	N/A	N/A

Summary

Catalyst Pharmaceuticals beats Aktis Oncology on 8 of the 13 factors compared between the two stocks.

How does Aktis Oncology compare to Veradermics?

Aktis Oncology (NASDAQ:AKTS) and Veradermics (NYSE:MANE) are both manufacturing companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Veradermics	N/A	N/A	N/A

In the previous week, Aktis Oncology had 2 more articles in the media than Veradermics. MarketBeat recorded 4 mentions for Aktis Oncology and 2 mentions for Veradermics. Veradermics' average media sentiment score of 0.54 beat Aktis Oncology's score of 0.47 indicating that Veradermics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veradermics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	180.16	N/A	N/A	N/A
Veradermics	N/A	N/A	N/A	N/A	N/A

28.8% of Aktis Oncology shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aktis Oncology presently has a consensus price target of $32.50, indicating a potential upside of 48.20%. Veradermics has a consensus price target of $109.00, indicating a potential upside of 13.65%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Aktis Oncology is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Aktis Oncology beats Veradermics on 6 of the 7 factors compared between the two stocks.

How does Aktis Oncology compare to Kiniksa Pharmaceuticals International?

Aktis Oncology (NASDAQ:AKTS) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Aktis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	180.16	N/A	N/A	N/A
Kiniksa Pharmaceuticals International	$677.56M	5.89	$59.01M	$0.90	57.66

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Aktis Oncology's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

In the previous week, Aktis Oncology had 1 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 4 mentions for Aktis Oncology and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.18 beat Aktis Oncology's score of 0.47 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aktis Oncology presently has a consensus price target of $32.50, suggesting a potential upside of 48.20%. Kiniksa Pharmaceuticals International has a consensus price target of $60.86, suggesting a potential upside of 17.28%. Given Aktis Oncology's higher possible upside, equities analysts plainly believe Aktis Oncology is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Summary

Kiniksa Pharmaceuticals International beats Aktis Oncology on 9 of the 12 factors compared between the two stocks.

Get Aktis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKTS vs. The Competition

Export

Metric	Aktis Oncology	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.17B	$2.95B	$4.29B	$12.05B
Dividend Yield	N/A	15.26%	10.25%	5.67%
P/E Ratio	N/A	13.63	22.29	24.42
Price / Sales	180.16	3,138.67	159.46	109.90
Price / Cash	N/A	26.81	40.19	37.92
Price / Book	N/A	4.79	26.92	6.82
Net Income	N/A	-$39.47M	$116.61M	$337.56M
7 Day Performance	15.60%	0.45%	0.25%	1.17%
1 Month Performance	12.17%	0.62%	0.25%	3.16%
1 Year Performance	N/A	16.42%	14.23%	30.58%

Aktis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTS Aktis Oncology	1.9243 of 5 stars	$21.93 flat	$32.50 +48.2%	N/A	$1.17B	$6.50M	N/A	76	Gap Down High Trading Volume
ERAS Erasca	2.3049 of 5 stars	$12.87 +7.5%	$20.11 +56.3%	+849.3%	$4.00B	N/A	N/A	120	Trending News
ORKA Oruka Therapeutics	2.7369 of 5 stars	$64.06 +6.5%	$131.30 +105.0%	+456.4%	$3.86B	N/A	N/A	N/A	News Coverage Analyst Downgrade Insider Trade
CPRX Catalyst Pharmaceuticals	3.6737 of 5 stars	$31.28 +0.0%	$32.00 +2.3%	+33.3%	$3.83B	$588.99M	17.98	80
MANE Veradermics	N/A	$90.74 -1.0%	$109.00 +20.1%	N/A	$3.79B	N/A	N/A	19	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKTS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aktis Oncology (AKTS) Competitors

AKTS vs. ERAS, ORKA, CPRX, MANE, and KNSA

How does Aktis Oncology compare to Erasca?

Summary

How does Aktis Oncology compare to Oruka Therapeutics?

Summary

How does Aktis Oncology compare to Catalyst Pharmaceuticals?

Summary

How does Aktis Oncology compare to Veradermics?

Summary

How does Aktis Oncology compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aktis Oncology (AKTS) Competitors

AKTS vs. ERAS, ORKA, CPRX, MANE, and KNSA

How does Aktis Oncology compare to Erasca?

Do insiders and institutionals have more ownership in AKTS or ERAS?

Which has stronger earnings and valuation, AKTS or ERAS?

Do analysts prefer AKTS or ERAS?

Is AKTS or ERAS more profitable?

Does the media prefer AKTS or ERAS?

Summary

How does Aktis Oncology compare to Oruka Therapeutics?

Is AKTS or ORKA more profitable?

Does the media favor AKTS or ORKA?

Do analysts recommend AKTS or ORKA?

Do insiders & institutionals believe in AKTS or ORKA?

Which has preferable earnings & valuation, AKTS or ORKA?

Summary

How does Aktis Oncology compare to Catalyst Pharmaceuticals?

Does the media favor CPRX or AKTS?

Which has better valuation and earnings, CPRX or AKTS?

Do institutionals and insiders believe in CPRX or AKTS?

Do analysts prefer CPRX or AKTS?

Is CPRX or AKTS more profitable?

Summary

How does Aktis Oncology compare to Veradermics?

Is AKTS or MANE more profitable?

Does the media favor AKTS or MANE?

Which has preferable valuation and earnings, AKTS or MANE?

Do institutionals & insiders believe in AKTS or MANE?

Do analysts recommend AKTS or MANE?

Summary

How does Aktis Oncology compare to Kiniksa Pharmaceuticals International?

Do institutionals and insiders hold more shares of AKTS or KNSA?

Which has better valuation and earnings, AKTS or KNSA?

Is AKTS or KNSA more profitable?

Does the media refer more to AKTS or KNSA?

Do analysts recommend AKTS or KNSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools